Contract Development And Manufacturing Organizations (CDMO)

14.05.2025 • Topics • Innovation

Motivation, Innovation, and the Power of Collaboration

Leading the Way in Pharmaceutical Manufacturing by Fostering an Agile Mindset and an Inclusive Culture.

09.05.2025 • News • Pharma

Hovione and Firstgene Announce Strategic Collaboration

Exclusive licensing and R&D collaboration between Hovione and Firstgene.

07.05.2025 • News

Aenova Launches Program to Accelerate Pharmaceutical Development

Aenova announces the launch of its Aenovation program. This initiative aims to accelerate the early development of pharmaceutical formulations.

06.05.2025 • News • Pharma

PCI Pharma Services Acquires Ajinomoto Althea

PCI Pharma Services has completed its acquisition of Ajinomoto Althea, a CDMO subsidiary of Ajinomoto.

24.04.2025 • News

Fujifilm Diosynth Biotechnologies & Regeneron Sign Manufacturing Agreement

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.

22.04.2025 • News

Suanfarma Appoints Pere Mañé as New CEO

CDMO Suanfarma appoints Pere Mañé Godina as its new CEO, marking the beginning of a new chapter for the company, focused on industrial consolidation, sustainable innovation, and global expansion.

15.04.2025 • News

Meribel Pharma Solutions Launches

A new, mid-size Contract Development Manufacturing Organisation (CDMO), Meribel Pharma Solutions, has launched today with an extensive integrated network across Europe.

03.04.2025 • News

HAS Acquires Cerbios-Pharma

HAS Healthcare Advanced Synthesis (HAS) recently announced the planned acquisition of Cerbios-Pharma (Cerbios), a globally recognized manufacturer of chemical and biological APIs, including antibody-drug conjugates (ADCs).

11.03.2025 • News

Syngene Acquires its First US Manufacturing Facility

Syngene, a global contract research, development, and manufacturing organization (CRDMO), recently announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.

10.03.2025 • News

Axplora Expands Capabilities at Le Mans Site

Axplora, an API small molecule and ADC (antibody-drug conjugate) manufacturer, is strengthening its position in the commercial manufacturing ADCs by launching a cutting-edge payload manufacturing workshop at its Le Mans site (France).

10.03.2025 • News

Adragos Pharma Commissions New Liquid Filling Line at German Site

German contract development and manufacturing organization (CDMO) Adragos Pharma has completed a €4 million project to install and commission a new, cGMP-compliant liquid drug filling line and associated cartoning machine at its plant in Leipzig, Germany.

06.03.2025 • News

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.

26.02.2025 • News

Granules India Buys Swiss CDMO Senn Chemicals

Indian pharmaceutical company Granules India has agreed to acquire Senn Chemicals, a Swiss-based contract development and manufacturing organization (CDMO) specializing in peptides. The closing of the deal, which is subject to certain conditions, is expected to occur in the first half of 2025. Financial details of the transaction were not disclosed.

06.02.2025 • News

Jabil Acquires CDMO Pharmaceutics International

Jabil, a global provider of engineering, manufacturing, and supply chain solutions, has acquired Pharmaceutics International (Pii), a US contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing. Financial details of the transaction, which was completed on Feb. 3, 2025, were not given.

04.02.2025 • News

Upperton Completes Sterile Manufacturing Facility in UK

UK contract development and manufacturing organization (CDMO) Upperton Pharma Solutions, has completed its new sterile manufacturing facility in Nottingham, UK, expanding its capacity in addition to its existing 50,000-square-foot site at Trent Gateway.

04.02.2025 • News

Solvias Opens New Testing Center in North Carolina, US

Solvias, a Switzerland-headquartered provider of chemistry, manufacturing, and control (CMC) analytics, has opened the first phase of its 50,000-square-foot testing center for biologics and cell and gene therapy in Research Triangle Park (RTP), North Carolina, US.

14.01.2025 • News

Alcami Announces CEO Transition

Alcami, a contract development and manufacturing organization (CDMO), recently announced the resignation of its CEO, Bill Humphries. Alcami’s Board Chair and former CEO Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations.

16.12.2024 • News

Lonza Outlines Restructuring Strategy and New Organizational Structure

At an investor update at the end of last week, Lonza has announced its "One Lonza" restructuring strategy, which aims to reorganize its CDMO business, simplify its operating model, enhance manufacturing and engineering, and expand its production footprint.

12.12.2024 • News • Strategy

Substantial Progresses in Sustainability Focus Areas

The Italian Olon Group, a leading international supplier of active pharmaceutical ingredients (APIs), presents the 2023 Corporate Sustainability Report and confirms the sustainability journey toward energy transition, investments in alternative energy sources, social and economic involvement and support for the communities in which it operates

09.12.2024 • News

SOCMA Publishes 2025 Contract Manufacturing Outlook

The Society of Chemical Manufacturers & Affiliates (SOCMA) has published the results of its 2025 Contract Manufacturing Outlook survey which reveals significant trends and insights into the contract manufacturing landscape.

02.12.2024 • News

Hovione Expands Spray Drying Capacities in the USA and Ireland

Lisbon, Portugal-headquartered Hovione has completed significant expansions in Europe and the USA. The investments at the facilities in East Windsor, New Jersey, and Ringaskiddy, Cork, significantly increase the global capacities of the CDMO (contract development and manufacturing organization) for spray drying for pharma applications and improve the sites' capabilities.

29.11.2024 • News

Samsung Biologics Signs Manufacturing Deal with European Pharmaceutical Company

Samsung Biologics, a global contract development and manufacturing organization (CDMO), recently announced a series of manufacturing deals with a Europe-based pharmaceutical company.

21.11.2024 • News

Avantor Opens New US Innovation Center in Bridgewater

Avantor has opened its latest Innovation Center in Bridgewater, New Jersey, US, “to support the growing demands for monoclonal antibodies, cell and gene therapy and mRNA workflows.” The new center is now part of the company’s network of 13 global research and innovation centers.

20.11.2024 • News

Siegfried Opens New Drug Substances R&D Center in Evionnaz

Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried inaugurated its new global research and development (R&D) center for drug substances at its site in Evionnaz, Switzerland. The 4,500 m2 center houses chemical and analytical facilities, laboratories, and technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.

12.11.2024 • News

Lonza to Expand Bioconjugation in Visp, Switzerland

Lonza, a global contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutraceutical markets, announced today that it will invest in additional bioconjugation capabilities in Visp, Switzerland.

11.11.2024 • News

Avid Bioservices to Be Acquired by GHO Capital and Ampersand

US-headquartered Avid Bioservices, a biologics-oriented CDMO, will be acquired by funds managed by GHO Capital Partners and Ampersand Capital Partners in an all-cash transaction valued at approximately $1.1 billion. The three companies have signed a corresponding agreement.

05.11.2024 • News

Ardena Expands European Bioanalytical Capabilities

Belgium-headquartered pharmaceutical contract development and manufacturing organization (CDMO) Ardena announced plans to expand its bioanalytical services in the Netherlands. As part of the investment, the company plans to establish a new bioanalytical laboratory at its Pivot Park facility in Oss, as well as additional capacity and new GLP capabilities at its bioanalytical center of excellence in Assen.

31.10.2024 • News

Sterling Pharma Solutions Expands GMP ADC Manufacturing Capacity

Sterling Pharma Solutions, a global contract development and manufacturing organization (CDMO), today announced the second phase of an expansion strategy at its Deeside, UK site to support antibody-drug conjugate (ADC) development, with a more than £10 million (€11.9 million) investment to increase GMP bioconjugation capacity.

25.10.2024 • News

Rentschler Plans New Buffer Media Facility at its Headquarters

In a move to further increase production efficiency and modernize the site, German contract development and manufacturing organization (CDMO) Rentschler Biopharma plans to construct a new buffer media station at its company headquarters in Laupheim. According to Rentschler, this is the largest single investment in the German site.

17.10.2024 • News

Cambrex Opens New Stability Storage Facility

Today, Cambrex announced its stability storage business, Q1 Scientific, and opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to North America's pharmaceutical, medical device, and life sciences industries.